Human kallikrein 10 ELISA development and validation in breast cancer sera

King, Lindsay; Li, Yong; Bouh, K. Cheikh Saad; Pedneault, Marc; Chu, Chee-Wui

doi:10.1016/j.clinbiochem.2007.05.008

Cited by 8 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the in vitro inhibition of KLK1 suppresses the invasiveness of breast cancer cells, and therefore it could be a defence mechanism [58]. On the other hand, KLK-mediated degradation of extracellular matrix proteins facilitates tumor cell invasion and metastasis [59], and higher serum levels of other kallikreins such as KLK5 [60], KLK10 [61], and KLK14 [62] have been found in women with breast cancer when compared to healthy ones. Hormonal regulation of KLK1 expression was suggested in human prostate and breast tissues [63] and its salivary secretion was proposed as modulated by age [64].…”

Section: Discussionmentioning

confidence: 99%

Changes in Serum and Salivary Proteins in Canine Mammary Tumors

Franco‐Martínez

Gelemanović

Horvatić

et al. 2020

Animals

View full text Add to dashboard Cite

The aim of this study was to evaluate changes in serum and saliva proteomes in canine mammary tumors (CMT) using a high-throughput quantitative proteomic analysis in order to potentially discover possible biomarkers of this disease. Proteomes of paired serum and saliva samples from healthy controls (HC group, n = 5) and bitches with CMT (CMT group, n = 5) were analysed using a Tandem Mass Tags-based approach. Twenty-five dogs were used to validate serum albumin as a candidate biomarker in an independent sample set. The proteomic analysis quantified 379 and 730 proteins in serum and saliva, respectively. Of those, 35 proteins in serum and 49 in saliva were differentially represented. The verification of albumin in serum was in concordance with the proteomic data, showing lower levels in CMT when compared to the HC group. Some of the modulated proteins found in the present study such as haptoglobin or S100A4 have been related to CMT or human breast cancer previously, while others such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D are described here for the first time. Our results indicate that saliva and serum proteomes can reflect physiopathological changes that occur in CMT in dogs and can be a potential source of biomarkers of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Changes in Serum and Salivary Proteins in Canine Mammary Tumors

Franco‐Martínez

Gelemanović

Horvatić

et al. 2020

Animals

View full text Add to dashboard Cite

show abstract

“…For example, KLK10 overexpression predicts poor survival in epithelial ovarian cancer (Luo et al, 2003; Shvartsman et al, 2003), but may be associated with better prognosis in high‐grade serous ovarian cancer (Geng et al, 2018). Similarly, the upregulated KLK10 is only evident in a subset of breast cancer patients at both early and late disease stages (Ewan King et al, 2007). In this context, cancer classification should be considered when analyzing KLK10's function in cancer development.…”

Section: Discussionmentioning

confidence: 99%

“…Dysregulated KLK10 expression is also frequently observed in various cancer types. KLK10 levels in serum are significantly elevated in breast cancer patients at early and late stages and in epithelial ovarian cancer patients with late‐stage high‐grade tumors (Ewan King et al, 2007; Luo et al, 2003; Shvartsman et al, 2003). KLK10 overexpression is also responsible for trastuzumab resistance in HER2‐positive breast cancer patients (Wang et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

KLK10 promotes the progression of KRAS mutant colorectal cancer via PAR1‐PDK1‐AKT signaling pathway

Wu,

Yan

et al. 2023

Cell Biology International

View full text Add to dashboard Cite

Kirsten rat sarcoma virus (KRAS) gene mutation is common in colorectal cancer (CRC) and is often predictive of treatment failure and poor prognosis. To understand the mechanism, we compared the transcriptome of CRC patients with wild‐type and mutant KRAS and found that KRAS mutation is associated with the overexpression of a secreted serine protease, kallikrein‐related peptidase 10 (KLK10). Moreover, using in vitro and in vivo models, we found that KLK10 overexpression favors the rapid growth and liver metastasis of KRAS mutant CRC and can also impair the efficacy of KRAS inhibitors, leading to drug resistance and poor survival. Further functional assays revealed that the oncogenic role of KLK10 is mediated by protease‐activated receptor 1 (PAR1). KLK10 cleaves and activates PAR1, which further activates 3‐phosphoinositide‐dependent kinase 1 (PDK1)‐AKT oncogenic pathway. Notably, suppressing PAR1‐PDK1‐AKT cascade via KLK10 knockdown can effectively inhibit CRC progression and improve the sensitivity to KRAS inhibitor, providing a promising therapeutic strategy. Taken together, our study showed that KLK10 promotes the progression of KRAS mutant CRC via activating PAR1‐PDK1‐AKT signaling pathway. These findings expanded our knowledge of CRC development, especially in the setting of KRAS mutation, and also provided novel targets for clinical intervention.

show abstract

“…breast [ 32 ], prostate [ 16 ] and gastric cell [ 33 ], including ovarian cell line [ 34 ]. Noteworthy is that overexpression of KLK10 was found in malignant sample subsets (tissues or sera) in cancer types in which KLK10 was shown experimentally as tumor suppressor; breast [ 35 ], prostate [ 19 ], gastric [ 36 ] and ovary [ 20 , 27 ]. Taken together, the antitumor role of KLK10 may be understood only in relation to the context of the given study as regard type of tissue and the underlying pathophysiologic processes [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

KLK10 exon 3 unmethylated PCR product concentration: a new potential early diagnostic marker in ovarian cancer? - A pilot study

et al. 2018

View full text Add to dashboard Cite

BackgroundKLK10 exon 3 hypermethylation correlated to tumor-specific lack of KLK10 expression in cancer cell lines and primary tumors. In the present study we investigate the possible role of KLK10 exon 3 methylation in ovarian tumor diagnosis and prognosis.ResultsQualitative methylation-specific PCR (MSP) results did not show statistically significant differences in patient group samples (normal and tumor) where all samples were positive only for the unmethylated-specific PCR except for two malignant samples that were either doubly positive (serous carcinoma) or doubly negative (Sertoli-Leydig cell tumor) for the two MSP tests. However, KLK10 exon 3 unmethylated PCR product concentration (ng/μl) showed statistically significant differences in benign and malignant patient group samples; mean ± SD (n): tumor: 0.077 ± 0.035 (14) and 0.047 ± 0.021 (15), respectively, p-value = 0.011; and normal: 0.094 ± 0.039 (7) and 0.046 ± 0.027 (6), respectively, p-value = 0.031. Moreover, ROC curve analysis of KLK10 exon 3 unmethylated PCR product concentration in overall patient group samples showed good diagnostic ability (AUC = 0.778; p-value = 0.002). Patient survival (living and died) showed statistically significant difference according to preoperative serum CA125 concentration (U/ml); median (n): 101.25 (10) and 1252 (5), respectively, p-value = 0.037, but not KLK10 exon 3 unmethylated PCR product concentration (ng/μl) in overall malignant patient samples; mean ± SD (n): 0.042 ± 0.015 (14) and 0.055 ± 0.032 (7), p-value = 0.228.ConclusionTo the best of our knowledge, this is the first report on KLK10 exon 3 unmethylated PCR product concentration as potential early epigenetic diagnostic marker in primary ovarian tumors. Taken into account the limitations in our study (small sample size and semi-quantitative PCR product analysis) further studies are strongly recommended.

show abstract

Human kallikrein 10 ELISA development and validation in breast cancer sera

Cited by 8 publications

References 7 publications

Changes in Serum and Salivary Proteins in Canine Mammary Tumors

Changes in Serum and Salivary Proteins in Canine Mammary Tumors

KLK10 promotes the progression of KRAS mutant colorectal cancer via PAR1‐PDK1‐AKT signaling pathway

KLK10 exon 3 unmethylated PCR product concentration: a new potential early diagnostic marker in ovarian cancer? - A pilot study

Contact Info

Product

Resources

About